Characterization of Lipid Nanoparticle Drug Formulations

Presented By: Judith Kuntsche, Ph.D., University of Southern Denmark, and Christoph Johann, Ph.D., Wyatt Technology
Presented Live: January 28, 2020

One of the primary challenges in developing and commercializing novel nanoparticle-based therapies is detailed characterization of the formulation components. FFF-DLS-MALS technology, which couples light scattering and other online detectors to field-flow fractionation, addresses this challenge. This webinar explores applications of FFF-DLS-MALS to characterize nanoparticle drug- and gene-delivery formulations, to determine high-resolution size distributions, drug loading and release, and particle structure.

The focus of this webinar is on colloidal lipid-based formulations, such as nanoemulsions and liposomes, that can be used to formulate poorly-water-soluble drugs in aqueous preparations to facilitate intravenous administration. FFF-DLS-MALS provides a very useful analytical tool to investigate the behavior of such formulations, even in complex physiological media such as serum. Case studies presented include: measurement of detailed liposome size distributions; assessment of drug release and transfer to cell membrane proxies; particle morphology; quantification of co-existing colloidal structures; and stability of the nanocarriers. The relevance of FFF-DLS-MALS to meeting FDA requirements for liposome formulations are also discussed.

Q&A Webinar Q & A